0.00Open0.05Pre Close0 Volume1.60K Open Interest5.00Strike Price0.00Turnover0.00%IV285.50%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma26.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ATAI Life Sciences Stock Discussion
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
atai Life Sciences (NASDAQ: ATAI)announced positive preliminary results from its Phase 1b trial of VLS-01, a proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT). The trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared to intravenous DMT in healthy participants.
Key findings include:
D...
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
You should check out $ATAI Life Sciences (ATAI.US)$ as well. 😉
$ATAI Life Sciences (ATAI.US)$ looks good too! It'll be interesting to see the advancements coming with their medicine. Especially with John Hopkins University doing similar research.
$ATAI Life Sciences (ATAI.US)$ looks good too! It'll be interesting to see the advancements coming with their medicine. Especially with John Hopkins University doing similar research.
$ATAI Life Sciences (ATAI.US)$ looks pretty good too!
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...
No comment yet